Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
21
06
2021
accepted:
09
02
2022
revised:
25
01
2022
pubmed:
4
3
2022
medline:
10
6
2022
entrez:
3
3
2022
Statut:
ppublish
Résumé
The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. The study included over 35,000 pancreatic cancer cases diagnosed during 2012-2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator. Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage. This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
Sections du résumé
BACKGROUND
The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom.
METHODS
The study included over 35,000 pancreatic cancer cases diagnosed during 2012-2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator.
RESULTS
Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage.
CONCLUSION
This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.
Identifiants
pubmed: 35236937
doi: 10.1038/s41416-022-01752-3
pii: 10.1038/s41416-022-01752-3
pmc: PMC9174285
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1774-1782Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
International Agency for Research on Cancer. Global Cancer Observatory. http://gco.iarc.fr/ (2020).
Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159:335.e5–49.e5.
doi: 10.1053/j.gastro.2020.02.068
Global Burden of Disease Study (GBD) Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934–47.
doi: 10.1016/S2468-1253(19)30347-4
McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS, et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24:4846–61.
doi: 10.3748/wjg.v24.i43.4846
pubmed: 30487695
Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505.
doi: 10.1016/S1470-2045(19)30456-5
pubmed: 31521509
Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.
doi: 10.1016/S0140-6736(17)33326-3
pubmed: 29395269
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl J Med. 2018;379:2395–406.
doi: 10.1056/NEJMoa1809775
pubmed: 30575490
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268:215–22.
doi: 10.1097/SLA.0000000000002705
pubmed: 29462005
Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, de Hingh I, et al. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. Eur J Cancer. 2020;125:83–93.
doi: 10.1016/j.ejca.2019.11.002
pubmed: 31841792
Ahola R, Sand J, Laukkarinen J. Centralization of pancreatic surgery improves results: review. Scand J Surg. 2020;109:4–10.
doi: 10.1177/1457496919900411
pubmed: 31969066
Latenstein AEJ, Mackay TM, van der Geest LGM, van Eijck CHJ, de Meijer VE, Stommel MWJ, et al. Effect of centralization and regionalization of pancreatic surgery on resection rates and survival. Br J Surg. 2021;108:826–33.
doi: 10.1093/bjs/znaa146
pubmed: 33738473
Gooiker GA, Lemmens VE, Besselink MG, Busch OR, Bonsing BA, Molenaar IQ, et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg. 2014;101:1000–5.
doi: 10.1002/bjs.9468
pubmed: 24844590
Huang L, Jansen L, Balavarca Y, Babaei M, van der Geest L, Lemmens V, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med. 2018;16:125.
doi: 10.1186/s12916-018-1120-9
pubmed: 30126408
Madley-Dowd P, Hughes R, Tilling K, Heron J. The proportion of missing data should not be used to guide decisions on multiple imputation. J Clin Epidemiol. 2019;110:63–73.
doi: 10.1016/j.jclinepi.2019.02.016
pubmed: 30878639
Ro C, Chai W, Yu VE, Yu R. Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment. Chin J Cancer. 2013;32:312–24.
doi: 10.5732/cjc.012.10295
pubmed: 23237225
Cabasag CJ, Arnold M, Piñeros M, Morgan E, Brierley J, Hofferkamp J, et al. Population-based cancer staging for oesophageal, gastric, and pancreatic cancer 2012–2014: International Cancer Benchmarking Partnership SurvMark-2. Int J Cancer. 2021. https://doi.org/10.1002/ijc.33679 .
doi: 10.1002/ijc.33679
pubmed: 33990959
US Preventive Services Task Force. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA. 2019;322:438–44.
doi: 10.1001/jama.2019.10232
Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13:66–74.
doi: 10.1038/nrc3420
pubmed: 23222481
Del Chiaro M, Segersvard R, Lohr M, Verbeke C. Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol. 2014;20:12118–31.
doi: 10.3748/wjg.v20.i34.12118
pubmed: 25232247
Tas F, Sen F, Keskin S, Kilic L, Yildiz I. Prognostic factors in metastatic pancreatic cancer: older patients are associated with reduced overall survival. Mol Clin Oncol. 2013;1:788–92.
doi: 10.3892/mco.2013.131
pubmed: 24649248
He J, Edil BH, Cameron JL, Schulick RD, Hruban RH, Herman JM, et al. Young patients undergoing resection of pancreatic cancer fare better than their older counterparts. J Gastrointest Surg. 2013;17:339–44.
doi: 10.1007/s11605-012-2066-4
pubmed: 23184271
Amin S, Lucas AL, Frucht H. Evidence for treatment and survival disparities by age in pancreatic adenocarcinoma: a population-based analysis. Pancreas. 2013;42:249–53.
doi: 10.1097/MPA.0b013e31825f3af4
pubmed: 22836862
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl J Med. 2011;364:1817–25.
doi: 10.1056/NEJMoa1011923
pubmed: 21561347
Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, et al. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Ther Adv Gastroenterol. 2019;12:1756284819878660.
doi: 10.1177/1756284819878660
Latenstein AEJ, Mackay TM, Creemers GJ, van Eijck CHJ, de Groot JWB, Haj Mohammad N, et al. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Acta Oncol. https://doi.org/10.1080/0284186X.2020.1725241 (2020).
Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38:1763–73.
doi: 10.1200/JCO.19.02274
pubmed: 32105518
Makar M, Worple E, Dove J, Hunsinger M, Arora T, Oxenberg J, et al. Disparities in care: impact of socioeconomic factors on pancreatic surgery: exploring the National Cancer Database. Am Surg. 2019;85:327–34.
doi: 10.1177/000313481908500420
pubmed: 31043190
Wennervaldt K, Kejs AM, Lipczak H, Bartels P, Borre M, Fristrup CW, et al. Regional variation in surgery for pancreatic cancer in Denmark 2011–2015. Dan Med J. 2018;65:A5503.
Cancer Council. Optimal care pathway for people with pancreatic cancer. https://www.cancer.org.au/ocp (2021).
Reames BN, Blair AB, Krell RW, Groot VP, Gemenetzis G, Padussis JC, et al. Management of locally advanced pancreatic cancer: results of an international survey of current practice. Ann Surg. 2019. https://doi.org/10.1097/SLA.0000000000003568 .
doi: 10.1097/SLA.0000000000003568
Andersson TM, Rutherford MJ, Myklebust TA, Moller B, Soerjomataram I, Arnold M, et al. Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study. Br J Cancer. 2021;124:1026–32.
doi: 10.1038/s41416-020-01196-7
pubmed: 33293692
Rutherford MJ, Moller H, Lambert PC. A comprehensive assessment of the impact of errors in the cancer registration process on 1- and 5-year relative survival estimates. Br J Cancer. 2013;108:691–8.
doi: 10.1038/bjc.2013.12
pubmed: 23361055
Bray F, Ferlay J. Chapter 5: Data comparability and quality. In: Bray F, et al. editors. CI5: cancer incidence in five continents, volume XI. Lyon: International Agency for Research on Cancer; 2017. p. 101–19.
Yadav S, Sharma P, Zakalik D. Comparison of demographics, tumor characteristics, and survival between pancreatic adenocarcinomas and pancreatic neuroendocrine tumors: a population-based study. Am J Clin Oncol 2018;41:485–91.
doi: 10.1097/COC.0000000000000305
pubmed: 27322698
Genus TSE, Bouvier C, Wong KF, Srirajaskanthan R, Rous BA, Talbot DC, et al. Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015. Br J Cancer. 2019;121:966–72.
doi: 10.1038/s41416-019-0606-3
pubmed: 31649320